BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration Pneumonia

• Status: Completed
• Trial end date: 2005-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to determine the efficacy and safety of Moxifloxacin in comparison to Sulbactam/Ampicillin in the treatment of pulmonary abscesses and aspiration pneumonia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Ampicillin; Fluoroquinolones; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination; Sulbactam

Criteria

Inclusion Criteria:

• Male or female patients aged 18 years or above

• The primary diagnosis is community or hospital acquired primary pulmonary abscess or aspiration pneumonia, requiring initial parenteral treatment

Exclusion Criteria:

• Known hypersensitivity to fluoroquinolones and/or ß-lactams

• Patients with mechanical ventilation lasting more than 48 hours prior to enrollment, with poststenotic pneumonia, infarction pneumonia, pulmonary tuberculosis, lung abscess/pneumonia with concomitant endocarditis